Skip to main content
. 2022 Aug 30;36:103177. doi: 10.1016/j.nicl.2022.103177

Table 1.

Clinical and demographic characteristics of patients and healthy subjects.

Multiple sclerosis patients Healthy subjects
Sex, n (male/female) 150 (58/92) 100 (46/54)
Age (years), mean ± SD 45 ± 15 38 ± 13
EDSS score, median (range) 3.63 (0–8)
Disease course (RR/PMS) 92/58
Disease-modifying therapy (n) Untreated (15)
Interferon-beta (8)
Glatiramer acetate (7)
Dimethyl fumarate (26)
Fingolimod (16)
Natalizumab (3)
Rituximab (5)
Ocrelizumab (60)
Siponimod (2)
Teriflunomide
(8)